NCT05241444

CD4^LVFOXP3 in Participants With IPEX

Phase 1 Study of Autologous CD4^LVFOXP3 in Participants With Immune Dysregulation Polyendocrinopathy Enteropathy X-linked (IPEX) Syndrome

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Bacchetta, Rosa, MD · Academic / Other
• Sex: Male
• Age: 4 Months – 35 Years
• Healthy volunteers: Not accepted

Summary

This first-in-human, Phase 1 clinical trial will test the feasibility of the manufacturing and the safety of the administration of CD4\^LVFOXP3 in up to 30 evaluable human participants with IPEX and evaluate the impact of the CD4\^LVFOXP3 infusion on the disease.

Detailed description

Treatment with CD4\^LVFOXP3 is expected to replace the defective Treg cells of the participants, and restore control of the immune system and therefore ameliorate symptoms of IPEX. We expect to learn the following from this study: 1. That CD4\^LVFOXP3 can be consistently produced and be of expected quality to be used in humans, 2. That CD4\^LVFOXP3 are safe in children and young adults with IPEX, and determine its effects, both good and bad, 3. That CD4\^LVFOXP3 can improve overall health and allow reduction of medication/s. This Phase 1 (feasibility and safety) trial will gather data about CD4\^LVFOXP3 in vivo persistency and early signs of impact on symptoms of IPEX.

Conditions

• IPEX

Interventions

Type	Name	Description
BIOLOGICAL	CD4^LVFOXP3	Infusion of autologous CD4+ T cells that have undergone lentiviral-mediated gene transfer of: i) healthy human FOXP3 gene leading to persistent high FOXP3 expression and acquisition of Treg-like cell function; and ii) human CD271 surface marker gene that allows tracking and quantification of the CD4\^LVFOXP3 in the blood.

Timeline

• Start date: 2022-03-22
• Primary completion: 2027-02-01
• Completion: 2037-02-01
• First posted: 2022-02-15
• Last updated: 2025-05-22

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study